Macular Vessels Density Before and After PRP in Patients With Proliferative Diabetic Retinopathy
Launched by MINIA UNIVERSITY · Jul 14, 2021
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
The global prevalence of diabetes mellitus in 2019 is estimated to be 9.3% (463 million people).1 Diabetic retinopathy (DR) is microangiopathy characterized by capillary non- perfusion, microaneurysms (MAs), and retinal ischemia. 2It may cause many complications, such as diabetic macular edema (DME) and diabetic macular ischemia (DMI).3 Capillary ischemia decreases the nutrition of the retina and causes hypoxia which results in increased level of vascular endothelial growth factor (VEGF), which promotes angiogenic responses causing both neovascularization (proliferative diabetic retinopathy...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with type 2 diabetes with PDR
- • treatment-naive PDR diabetic patients diagnosed clinically and by the presence of neovascularization on optic disc (NVDs) or elsewhere (NVEs) on fluorescein angiography.
- Exclusion Criteria:
- • Patients with significant media opacity decreasing image quality
- • -. Eyes with significant macular edema
- • patients with glaucoma, uveitis, previous intraocular surgery, and history of previous treatment for diabetic retinopathy including anti-VEGF and laser
- • patients with low signal strength index (SSI; \<50)
- • presence of 1 or more blink artifacts
- • poor fixation leading to motion artifacts.
About Minia University
Minia University is a prestigious educational institution located in Egypt, dedicated to advancing medical research and clinical trials. With a commitment to fostering innovation and improving healthcare outcomes, the university collaborates with a diverse range of stakeholders, including healthcare professionals and researchers. Minia University aims to enhance clinical practices through rigorous research methodologies and ethical standards, contributing to the body of knowledge in the medical field while addressing local and global health challenges. The university's clinical trial initiatives are designed to evaluate new treatments and interventions, ensuring a positive impact on patient care and community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minya, , Egypt
Patients applied
Trial Officials
Ahmed Shawkat, Prof Dr
Study Director
Minia University Hospital
Mohamed Farouk, Prof Dr
Study Director
Minia University Hospital
Mohamed Salah, Doctor
Principal Investigator
Minia University Hospital
Asmaa Anwar, Doctor
Study Director
Minia University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials